Abstract
AbstractNovel platinum(II) and palladium(II) complexes [PtCl2(HL1)] (3a), [NH2(CH3)2][PtCl2(L1)] (3b), [PdCl2(HL1)] (4a), [NH2(CH3)2][PdCl2(L1)] (4b) and [PdCl(CH3CN)(L1)] (4c), where HL1 = 4‐(2‐hydroxybenzoyl)‐2‐(pyridin‐2‐yl)‐1H‐pyrazol‐3‐ol, have been synthesised as potential anticancer compounds. Protonation constants of the ligand were determined by pH‐metric titration (log K1 = 7.74 ± 0.03; log K2 = 2.85 ± 0.05). The solid‐state structures of complexes 3b and 4c have been determined by X‐ray diffraction, showing square‐planar coordination geometry of PtII and PdII ions. In addition, the compounds have been characterised by IR, 1H NMR and FAB mass spectrometry. The results of preliminary studies on the cytotoxic activity in vitro against HL‐60 and NALM‐6 leukaemia cell lines are also reported and the IC50 values compared with those of the metal‐free ligand and cisplatin. Cytotoxic evaluation revealed that PtII and PdII complexes were active in the micromolar concentration range.(© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
